A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Study Identifier
M16-067
CT.gov Identifier
NCT03398148
EudraCT Identifier
2016-004677-40
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Results Available

Protocol
Available Language(s): English
Download document(s)
Statistical Analysis Plan
Available Language(s): English
Download document(s)
Plain Language Summary
Available Language(s): English, English, Dutch, Italian, Japanese, Japanese, Polish, Turkish, Ukrainian
Download document(s)
Scientific Result Summary
Available Language(s): English
Download document(s)

Study Details

Medical Condition
  • Ulcerative Colitis (UC)
    • Study Drug
  • risankizumab IV
  • placebo for risankizumab
  • risankizumab SC
    • Phase
    Phase 2/Phase 3
    Sex
    Female & Male
    Age
    16 - 80 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Male or female aged \>=18 to \<= 80 years at the Baseline Visit. Where locally permissible, subjects 16 to \< 18 years of age who meet the definition of Tanner stage 5 for development at the Baseline Visit. * Confirmed diagnosis of ulcerative colitis (UC) for at least 3 months prior to Baseline. * Active UC as assessed by Adapted Mayo Score and Endoscopic Subscore. * Demonstrated intolerance or inadequate response to conventional therapy and tofacitinib (not a biologic) and one or more biologic therapies. * Females must be postmenopausal for more than 1 year or surgically sterile or practicing specific forms of birth control.
    Exclusion Criteria:
    * Participant with a current diagnosis of Crohn's disease (CD), inflammatory bowel disease-unclassified (IBD-U) or a history of radiation colitis or ischemic colitis. * Participant receiving prohibited medications and treatment. * Extent of inflammatory disease limited to the rectum as assessed by screening endoscopy. * Participant with currently known complications of UC (e.g., megacolon). * No known active Coronavirus Disease - 2019 (COVID-19) infection.

    Protocol Summary

    The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis (UC), and to identify the appropriate induction dose of risankizumab for further evaluation in Sub-Study 2.

    The objective of Sub-Study 2 is to evaluate the efficacy and safety of risankizumab compared to placebo in inducing clinical remission in subjects with moderately to severely active UC.

    Study Locations

    Location
    Status
    Location
    DHAT Research Institute /ID# 158226
    Garland, Texas, United States, 75044-2208
    33.7 miles (53.9 km) away from your location
    Status
    Not applicable